Tag - Corbus Pharmaceuticals

Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present in a fireside chat at the 7th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 15th at 2:30 p.m. EST in New York, NY. Read more >>

Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (“FDA”) regarding the design of its next study of lenabasum (formerly known as anabasum), a novel, oral, pro-resolving drug, in the treatment of cystic fibrosis (“CF”). Read more >>

From Startup to Publicly Traded Company: Story of Corbus Pharmaceuticals

The following post is from Antonette Ho, Group Operations Manager at Boston Harbor Angels.
Corbus Pharmaceuticals Wins Exit of the Year Award
Corbus Pharmaceuticals is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. One of the great successes in the Boston Harbor Angels portfolio, Corbus was awarded Exit of the Year at the annual end-of-year general meeting in December 2017. Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President […]

Boston Harbor Angels Awards Portfolio Companies at Annual Meeting

Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its annual end-of-year general meeting.
Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ
Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc.
IT Startup of the Year Award: Wasabi
The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi.
The group also honored Mic […]

Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,820,964 to the Company with claims covering the use of pharmaceutical compositions comprising anabasum for the treatment of multiple fibrotic diseases, including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis as well as others. Read more >>

Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology (“ACR”) 2017 Annual Meeting being held November 3-8, 2017 in San Diego, California. Read more >>